Bayer Expects Nubeqa Peak Sales of More Than $3.4 Billion After Positive Trial Data
February 18 2022 - 3:27AM
Dow Jones News
By Cristina Roca
Bayer AG said late Thursday that it now expects peak sales for
Nubeqa to top 3 billion euros ($3.41 billion) after disclosing
positive Phase 3 trial data for the drug.
The German chemical and pharmaceutical company said Nubeqa, an
oral androgen receptor inhibitor, in combination with androgen
deprivation therapy and docetaxel, significantly increased overall
survival in patients with metastatic hormone-sensitive prostate
cancer.
Write to Cristina Roca at cristina.roca@wsj.com
(END) Dow Jones Newswires
February 18, 2022 03:12 ET (08:12 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Apr 2023 to Apr 2024
